CSIMarket
 
Pelthos Therapeutics Inc   (NYSEAMER: PTHS)
 

Pelthos Therapeutics Inc's Customers Performance

PTHS



 
PTHS's Source of Revenues During the corresponding time, Pelthos Therapeutics Inc sequentially revenue grew by 16.16 %. While revenue at the Pelthos Therapeutics Inc 's corporate clients

List of PTHS Customers




for the same period Pelthos Therapeutics Inc sequentially revenue grew by 16.16 %.

List of PTHS Customers

Pelthos Therapeutics Inc's Business Units
Commercial operations    97.79 % of total Revenue
Research and Development operations    2.21 % of total Revenue






Pelthos Therapeutics Inc's Comment on Sales, Marketing and Customers



The Company serves patients using its product ZELSUVMI, focusing on payer channels including commercial, Medicaid, and Managed Medicaid. It offers co-pay cards and coupons for eligible commercially insured patients. In December 2025, the Company entered its first commercial agreement with a major Pharmacy Benefit Manager (PBM) through a Group Purchasing Organization that works with manufacturers on behalf of one of the largest PBMs in the U.S., managing prescription drug benefits for over 20 million covered lives. The Company sources raw materials from third-party suppliers and utilizes third-party logistics vendors for transportation within its supply chain. Manufacturing is conducted at the Company's primary facility in North Carolina. The active pharmaceutical ingredient (API) is shipped to a third-party contract manufacturing organization (CMO) for conversion into the finished product, which is then distributed by a third-party logistics provider.





Pelthos Therapeutics Inc’s Comment on Sales, Marketing and Customers


The Company serves patients using its product ZELSUVMI, focusing on payer channels including commercial, Medicaid, and Managed Medicaid. It offers co-pay cards and coupons for eligible commercially insured patients. In December 2025, the Company entered its first commercial agreement with a major Pharmacy Benefit Manager (PBM) through a Group Purchasing Organization that works with manufacturers on behalf of one of the largest PBMs in the U.S., managing prescription drug benefits for over 20 million covered lives. The Company sources raw materials from third-party suppliers and utilizes third-party logistics vendors for transportation within its supply chain. Manufacturing is conducted at the Company's primary facility in North Carolina. The active pharmaceutical ingredient (API) is shipped to a third-party contract manufacturing organization (CMO) for conversion into the finished product, which is then distributed by a third-party logistics provider.








PTHS's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Pelthos Therapeutics Inc 80.19 0.00 -51.59 92
SUBTOTAL 0.00 0.00 0.00 -

Sources: Pelthos Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Pelthos Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Pelthos Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.